Table III.
Authors/(Refs.) | Data | Treatment | Patients (no.) | Global QOL | Fatigue | Nausea and vomiting | Pain | Dyspnoea | Insomnia | Appetite loss | Constipation |
---|---|---|---|---|---|---|---|---|---|---|---|
Rosell et al (21) | p-value | CDDP | 171 | 0.939 | 0.955 | 0.149 | 0.058 | 0.163 | 0.985 | 0.084 | 0.468 |
CBDCA | 172 | ||||||||||
Scagliotti et al (22) | Mean change from baselineb | CDDP | 132 | - | 5 | 11 | - | - | - | −1 | - |
CBDCA | 99 | - | 10 | 4 | 2 | - | |||||
Danson et al (23) | Percentage change from baselineb | CDDP | 50 | 50%d | 70%d | 48%d | 36%c | 40%c | 20%d | 19%d | 21%d |
CBDCA | 54 | 40%d | 49%d | 28%d | 46%c | 25%c | 35%d | 39%d | 2%d | ||
Paccagnella et al (24) | p-value | CDDP | 39 | 0.40 | 0.15 | <0.001 | 0.47 | 0.17 | 0.03 | 0.01 | 0.01 |
CBDCA | 38 | ||||||||||
Rudd et al (25) | Median change from baseline (interquartile range) | CDDP | 120 | 0 | 0.33 | 0 | 0 | 0 | 0 | 0 | 0 |
(−1.0–0.50) | (−0.33–0.67) | (0–0.50) | (−0.50–0)) | (0–0) | (−1.0–0) | (−1.0–0) | (0–0) | ||||
CBDCA | 112 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
(−1.0–1.0) | (−0.33–0.67) | (0–0) | (−0.50–0) | (−1.0–0) | (−1.0–1.0) | (−1.0–0) | (0–0) | ||||
Booton et al (26) | Median change from baseline (interquartile range) | CDDP | 22 | 0 | 11 | 0 | 0 | 0 | −33 | 0 | 0 |
CBDCA | 26 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
QOL scales, a higher score indicates a better global QOL and a greater severity of symptoms (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation);
value that was shown on a chart;
improvement;
deterioration. CDDP, cisplatin; CBDCA, carboplatin.